A 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Japanese Subjects

Trial Profile

A 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Japanese Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Ichorcumab (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 30 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 16 Jun 2017 Planned End Date changed from 8 Feb 2018 to 23 Jun 2018.
    • 16 Jun 2017 Planned primary completion date changed from 7 Dec 2017 to 23 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top